Evidence for Virus-Mediated Oncogenesis in Bladder Cancers Arising in Solid Organ Transplant Recipients

Authors
Gabriel J Starrett¹, Kelly Yu², Yelena Golubeva³, Petra Lenz³, Mary L Piaskowski¹, David Petersen¹, Michael Dean², Ajay Israni⁴, Brenda Y Hernandez⁵, Thomas C Tucker⁶, Iona Cheng⁷, Lou Gonsalves⁸, Cyllene R Morris⁹, Shehnaz K Hussain¹⁰, Charles F Lynch¹¹, Reuben S Harris¹², Ludmila Prokunina-Olsson², Paul Meltzer¹, Christopher B Buck¹*, and Eric A Engels²*.

Affiliations
¹ CCR, NCI, NIH, Bethesda, MD, USA
² DCEG, NCI, NIH, Rockville, MD, USA
³ Leidos Biomedical Research Inc., Frederick, MD, USA
⁴ Department of Medicine, Nephrology Division, Hennepin Healthcare System, University of Minnesota-Twin Cities, Minneapolis, MN, USA
⁵ University of Hawai'i Cancer Center, Honolulu HI, USA
⁶ The Kentucky Cancer Registry, University of Kentucky, Markey Cancer Center, KY, USA
⁷ University of California-San Francisco, Department of Epidemiology & Biostatistics, and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
⁸ Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA
⁹ California Cancer Reporting and Epidemiologic Surveillance Program, UC Davis Comprehensive Cancer Center/UC Davis Health, Davis, CA, USA
¹⁰ Cedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
¹¹ The Iowa Cancer Registry, The University of Iowa, Iowa City, IA, USA
¹² Howard Hughes Medical Institute, University of Minnesota-Twin Cities, Minneapolis, MN, USA

*These authors contributed equally

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Corresponding author: Gabriel J Starrett, gabe.starrett@nih.gov

Author Contributions:
GJS, CBB, and EAE interpreted data, conceptualized, and drafted the initial manuscript. GJS performed data analysis, statistics, and generated figures. EAE and KY analyzed and summarized case clinical data. GJS, MLP, and DP extracted nucleic acids and prepared libraries from tumor specimens. MD, PM, LP, and RSH provided key resources and interpreted data. YG performed IHC and PL reviewed and analyzed histology for all specimens. KY, AI, TCT, IC, LG, CRM, CFL, BYH, and SKH coordinated case and specimen identification and acquisition from registry hospitals. All authors read and approved the final manuscript.

Competing Interest Statement: RSH is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc. The remaining authors have no competing interests to declare.

Preprint Servers: MedRXiv, https://www.medrxiv.org/content/10.1101/2021.11.11.21266080v1

Keywords: Bladder cancer, polyomavirus, papillomavirus, torque teno virus, solid organ transplant recipient

This PDF file includes:
- Main Text, words 7454
- Figures 1 to 6
- Tables 1 and 2
Main Text

Abstract

A small percentage of bladder cancers in the general population have been found to harbor DNA viruses. In contrast, up to 25% of tumors of solid organ transplant recipients, who are at an increased risk of developing bladder cancer and have overall poorer outcome, harbor BK polyomavirus (BKPyV). To better understand the biology of the tumors and the mechanisms of carcinogenesis from potential oncoviruses, we performed whole genome and transcriptome sequencing on bladder cancer specimens from 43 transplant patients. Nearly half of tumors from this patient population contained viral sequences. The most common were from BKPyV (N=9, 21%), JC polyomavirus (N=7, 16%), carcinogenic human papillomaviruses (N=3, 7%), and torque teno viruses (N=5, 12%). Immunohistochemistry revealed variable Large T antigen expression in BKPyV-positive tumors ranging from 100% positive staining of tumor tissue to less than 1%. In most cases of BKPyV-positive tumors, the viral genome appeared to be clonally integrated into the host chromosome consistent with microhomology-mediated end joining and coincided with focal amplifications of the tumor genome similar to other virus-mediated cancers. Significant changes in host gene expression consistent with the functions of BKPyV Large T antigen were also observed in these tumors. Lastly, we identified four mutation signatures in our cases with those attributable to APOBEC3 and SBS5 being the most abundant. Mutation signatures associated with the antiviral drug, ganciclovir, and aristolochic acid, a nephrotoxic compound found in some herbal medicines, were also observed. The results suggest multiple pathways to carcinogenesis in solid organ transplant recipients with a large fraction being virus-associated.

Author Summary

Solid organ transplant recipients are at a significantly increased risk for developing bladder cancer compared to the general population, suggesting a potential infectious origin to these
tumors. This study identifies that BK polyomavirus, JC polyomavirus, human papillomaviruses,
and anelloviruses are commonly found in bladder tumors of solid organ transplant recipients. In
most cases when detected, BK polyomavirus is integrated into the tumor genome and
associates with genomic structural changes and distinct gene expression through the activity of
viral oncogenes. Additionally, mutational signature analysis suggests that a subset of tumors of
solid organ transplant recipients develop through distinct mutagenic processes compared to the
general population. Together these results indicate multiple distinct mechanisms of
carcinogenesis in bladder cancers of solid organ transplant recipients that may have
implications for prevention, treatment, and outcome.

Introduction

At least 20% of all cancers are attributable to viral, bacterial, or parasitic infections (1). The
advent of high-throughput deep sequencing has provided unprecedented opportunities to learn
how infectious agents are involved in cancer in an unbiased manner. Several previous studies
have searched for microbial nucleotide sequences in The Cancer Genome Atlas (TCGA), the
International Cancer Genome Consortium (ICGC), and PanCancer Analysis of Whole Genomes
(PCAWG) datasets (2, 3). In addition to confirming known associations, such as the presence of
human papillomaviruses (HPVs) in cervical cancer, these studies also uncovered rare cases in
which viral sequences were unexpectedly found in other major cancers affecting the general
population (3).

Despite the immense amount of tumor sequencing data generated to date, the identification of
microorganisms in common cancers through these studies has been limited. A more focused
assessment of groups at increased risk for virus-associated cancers may be needed. In
particular, oncogenic viruses may contribute to a larger fraction of cancer cases among
immunosuppressed individuals, such as those with human immunodeficiency virus (HIV)
infection and organ transplant recipients. These populations have been previously shown to be
at increased risk for developing papillomavirus-mediated cancers, and the oncogenic viruses,
KSHV and Merkel cell polyomavirus, were discovered in these patients (4-6).

Roughly a dozen “high-risk” HPV types cause nearly all cervical cancers, a large majority of
other anogenital cancers, and about half of all oropharyngeal cancers (7). The carcinogenic
effects of these small circular double-stranded DNA viruses are primarily dependent on
expression of the E6 and E7 oncogenes which, among a wide range of other functions,
inactivate the tumor suppressor proteins p53 and Rb, respectively (8-12).

Polyomaviruses share many biological features with papillomaviruses. In particular,
polyomavirus T antigens perform many of the same functions as papillomavirus oncoproteins
and are similarly oncogenic in cellular and animal models (13). Merkel cell polyomavirus
(MCPyV) has been identified as an etiological factor in a rare skin cancer, Merkel cell carcinoma
(5, 14, 15). Another human polyomavirus, BK polyomavirus (BKPyV), has a long-debated
history as a candidate cancer-causing virus. Several case reports have described the detection
of BKPyV in bladder cancers arising in transplant recipients, and kidney recipients who develop
BKPyV viremia or BKPyV-induced nephropathy (BKVN) after transplant are at increased risk of
bladder cancer (16-19).

Similar to HPV-induced cervical and oropharyngeal cancers, bladder cancers exhibit somatic
point mutations that are largely attributable to the activity of APOBEC3 family cytosine
deaminases (20-22). These enzymes normally function as innate immune defenses against
viruses by deaminating cytosines in single-stranded DNA, leading to hypermutation of the viral
genome (23). Commonly, APOBEC3 enzymes, particularly APOBEC3A and APOBEC3B, can
become dysregulated and cause carcinogenic damage to cellular DNA during the development
of various types of cancer (24). APOBEC3A and APOBEC3B are upregulated in response to expression of HPV E6 and E7, and APOBEC3A can restrict HPV replication (25-29). The large T antigens (LTAgS) of BKPyV and JC polyomavirus (JCPyV, a close relative of BKPyV) also upregulate APOBEC3B expression and activity (30-32).

To characterize the mutational, transcriptomic, and viral landscapes of bladder cancers arising in immunosuppressed individuals, we evaluated archived tissues from 43 solid organ transplant recipients who developed this malignancy. We performed total RNA sequencing and whole genome sequencing (WGS) from these tissues. We utilized high-sensitivity methods and comprehensive reference sequences for conserved viral proteins to identify known viral species and to search for divergent viruses. Once viruses were identified, we further evaluated the sequence data for integration events, point mutations, mutation signatures, and differentially expressed genes to identify differences correlating with the presence of these viruses and their integration state.

Results

Bladder cancers from transplant recipients
The study population was comprised of 43 U.S. bladder cancer cases from patients who developed cancer after receiving solid organ transplantation (Table 1). Seventy percent were male and 70% non-Hispanic white. The median age at cancer diagnosis was 65 years (range: 27-82). The most commonly transplanted organ was the kidney (56%), followed by heart and/or lung (33%) and liver (9%). Primary tumors were roughly an equal mixture of high- and low-grade carcinomas diagnosed a median of 5.7 years after transplantation. Twelve cases were categorized as in situ as defined by the Surveillance, Epidemiology, and End Results (SEER) Program, with two of those cases being transitional cell carcinomas in situ and ten cases being noninvasive papillary transitional cell carcinomas. Invasive cases were mostly categorized into
the localized stage \((n=20, 46\%)\), which includes tumors that have invaded into the mucosa, submucosa, muscle or subserosa. The eleven remaining cases either had regional or distant invasion or metastasis. We successfully generated WGS data for 39 primary tumors, 3 metastases, and 3 normal tissues, with a median of 31x coverage across the human genome (range: 14-55x). We generated total RNA sequencing data for 42 primary tumors, 5 metastases, and 15 normal tissues, with a median of 30 million reads per sample (range: 4-65.5 million).

**Detection of viruses in bladder cancers from transplant recipients**

Analysis of WGS data for 39 primary tumors identified one or more virus species in 16 specimens (41\%) (Figure 1A). RNA sequencing on tumor samples for which WGS data could not be obtained revealed three additional cases containing viral sequences (45\% of samples overall). Among the 20 virus-positive primary tumors, the majority harbored BKPyV \((n=9)\) or JCPyV \((n=7)\). High-risk HPV genotypes 16 and 51 were detected in one and two tumors, respectively. A low-risk papillomavirus, HPV28, was observed in TBC33. One BKPyV-containing tumor (case TBC05) also harbored relatively abundant amounts of HPV20. Only two reads mapped to HPV20 in the RNA dataset for case TBC05. Sequencing of metastases confirmed the presence of BKPyV in TBC06, JCPyV in TBC34, and HPV16 in TBC10. Additionally, sequencing of two separate tumor sections for TBC03 and TBC09 confirmed the presence of BKPyV in both.

WGS from TBC16, TBC17, TBC18, TBC19, TBC20, TBC21, TBC22, TBC23, TBC24, TBC27 had low numbers of reads mapping to the BKPyV genome that were judged to be attributable to low levels of index-hopping from TBC01, a papillary urothelial neoplasm of low malignant potential (PUNLMP) that had extremely high BKPyV coverage and was sequenced in the same run. Considering this, along with the absence of RNA reads supporting the presence of BKPyV, we scored these tumors virus-negative.
A separate set of searches aimed at identifying divergent members of other virus groups revealed that several tumors (TBC08, TBC14, TBC25, TBC28, and TBC35) and normal tissues (TBC35, TBC28, TBC39) harbored torque teno virus (TTV) sequences from either WGS or RNA sequencing (Supplemental Table S3). Epstein Barr virus was most strongly detected in one normal lymph node (TBC23) and, at low levels, in tumors TBC07 and TBC08. Considering the stronger epidemiological evidence for BKPyV and bladder cancer and its abundance in these specimens, we focused the majority of our analysis on characterizing these tumors.

Features of BKPyV-positive tumors

BKPyV sequences detected in this study came from every genotype except IV (Figure 2A). One patient with a BKPyV-positive tumor had a documented history of BKVN. We identified unambiguous BKPyV integration sites in five of the nine BKPyV-positive tumors and in one normal tissue (Figure 2B & Table 2). For three tumors a single integration junction was identified, and in TBC02 three junctions were identified. In case TBC03, two separate sections from separate blocks of the primary tumor were sequenced. In one of the two sections, 11 integration junctions were identified across seven chromosomes. Only three of the junctions could be identified in the second section of the tumor, suggesting either that these junctions were not present throughout the tumor or there was insufficient tumor purity/sequencing depth to detect them.

Integration appeared consistent with a microhomology-mediated end-joining (MMEJ) model for integration, as 20 of 25 junctions (80%) had microhomology greater than or equal to 2 bp. In this model, which has previously been proposed for both HPV- and MCPyV-associated tumors (33-35), microhomologies between the virus and host genomes initiate DNA repair processes that can, in some cases, lead to tandem head-to-tail concatemeric repeats of the viral genome as
well as focal amplifications of the flanking host chromosome. Consistent with this model, focal amplifications adjacent to BKPyV integration sites were identified in three patient tumors. In TBC03, amplification of a 17 kb region of chromosome 1 flanking a multi-copy BKPyV integrant was observed in two tumor sections (Figure 2C). In TBC04, a 15 kb single-copy amplification of chromosome 3 was identified. Lastly, a 195 kb region of chromosome 6 was amplified next to the BKPyV integration junction in TBC08. Twenty-two of the identified 25 junctions (88%) intersected protein coding genes and thus might conceivably affect gene expression or function.

BKPyV RNA and DNA abundance by sequencing generally did not correspond to specimen tumor purity or the percentage of LTAg+ cells (Figure 3A and B). Gene level analysis of the RNA sequencing data revealed that nearly all polyomavirus-positive tumors predominantly expressed the T antigens, with little to no expression of the late genes VP1 and VP2 (encoding the major and minor capsid proteins, respectively) (Figure 3A and C, Supplemental Figure S1). The LTAg open reading frames (ORFs) in these cases were truncated before the helicase domain through deletions, frameshifts, or point mutations. An exception was the BKPyV-positive PUNLMP case TBC01, which showed balanced expression of both early and late regions.

BKPyV isolates found in cases of polyomavirus nephropathy typically have rearrangements in the regulatory region that enhance viral replication in cell culture. However, in this study, TBC01 was the only polyomavirus-positive tumor showing evidence of regulatory region rearrangements (Supplemental Figure S1).

Immunohistochemistry (IHC) for polyomavirus LTAg was performed on 18 specimens suspected to contain polyomaviruses and two negative control specimens determined to be free of detectable viral sequences. Control sections were negative for TAg staining, whereas 11 of the 18 specimens that contained polyomavirus sequences showed at least some evidence for TAg
positivity (Figure 3B and Supplemental Figure S1). Three tumors scored as BKPyV sequence-positive had strong to moderate LTAg staining in greater than 80% of tumor cells, but the other BKPyV-positive tumors had more variable staining. Moderate to weak staining was visible in less than 0.5% cells in the primary tumor for TBC06 (Figure 3D), but strong staining was observed in about 25% of cells in the metastasis. For TBC09, one sample of the tumor was >90% positive for LTAg staining and another sample was less than 25% positive (Supplemental Figure S1). The normal tissue for TBC09 showed BKPyV RNA and DNA coverage along a small portion of the regulatory region and small T antigen, but no staining for LTAg. Although TBC01 had very high levels of BKPyV DNA and RNA reads, it had the lowest observed proportion of LTAg-positive cells (<1% in a section that was >95% tumor). LTAg-positive cells in the TBC01 sample were almost entirely localized to the luminal margin of the tumor (Figure 3D).

Differential gene expression analysis for BKPyV-positive tumors versus virus-negative tumors revealed 1062 genes that were significantly differentially regulated in tumors harboring BKPyV (Figure 4A, Supplementary Table S4). Clustering all primary and metastatic tumors by genes with a greater than three-fold difference of expression in the above comparison, we identified three major groups that loosely correspond to the amount of BKPyV DNA and RNA in a tumor (Figure 4C). A notable exception is the BKPyV-positive tumor TBC01, which falls into the cluster mostly containing virus-negative tumors.

The cluster exclusively containing tumors harboring integrated BKPyV is defined by high expression of genes involved in DNA damage responses, cell cycle progression, angiogenesis, chromatin organization, mitotic spindle assembly and chromosome condensation/separation as well as some genes associated with neuronal differentiation. Overall, these tumors have relatively low expression of keratins and genes associated with cell adhesion. Genes previously shown to be associated with cell proliferation in bladder cancer, such as FGFR3, had
significantly lower expression in BKPyV-positive tumors relative to virus-negative tumors.

Notably, tumors harboring BKPyV had significantly higher average APOBEC3B expression compared to both normal tissues and tumors not containing any virus (Figure 4B). This observation is maintained after stratifying the cases by the germline variant, rs1014971, known to associate with increased APOBEC3B expression and bladder cancer risk with highest average APOBEC3B expression observed in tumors with both BKPyV and two copies of rs1014971 (Supplemental Figure S2).

In TBC03, the observed BKPyV integration into Breast Cancer Antiestrogen Resistance 3 (BCAR3) results in increased expression of the host gene. Further evaluation of RNA reads covering this region revealed a general enrichment of sense and antisense reads mapping to positions 93,688,393-93,704,476, corresponding to the amplified chromosomal region observed in the WGS dataset. There is an even greater enrichment of mapped reads between positions 93,694,469-93,696,857. No increases in expression in nearby host genes were observed for other cases and integration events.

Aside from integration related copy number changes (CNVs), large scale CNVs overall differed between BKPyV-positive and virus-negative tumors (Figure 5, Supplementary Table S6). BKPyV-positive tumors showed moderate enrichments for gains of chromosome segments 1q, 2p, 3p, 7q, 20q, and 22q, while losses of chromosome 2q, 6q, and 10q were also observed more frequently in BKPyV-positive tumors versus virus-negative tumors. Similar differences in copy numbers have been observed for virus-positive and virus-negative Merkel cell carcinoma (33).

**Features of other virus-positive tumors**

In the cases that were positive for JCPyV, DNA and RNA coverage depth was much lower than observed for BKPyV-positive tumors, and in several DNA-positive cases JCPyV transcription
was not detected (Figure 1). JCPyV reads were detected in three samples from case TBC12 including the primary tumor, tumor-positive lymph node, and adjacent normal bladder wall (Supplemental Figure S3). IHC detected sparse LTAg staining in JCPyV-positive case TBC13, but not in any tissue samples for TBC12.

For two of three cases harboring HPV types known to cause cervical cancer (HPV16 and HPV51), transcripts encoding the E6 and E7 oncogenes were detected (Supplemental Figure S4). In one HPV16+ case (TBC10), viral oncogene RNA expression was detected in both the primary and metastatic specimens. A possible HPV51 integration event in TBC32 appears to have involved a Mer4-int retrotransposon. Lastly, one case harbored DNA sequences aligning to HPV20 and a single case harbored DNA aligning to HPV28; however, no RNA reads were detected for these cutaneous HPV types (Supplemental Figure S4).

For the five TTV-positive tumors, the WGS analyses did not show evidence of integration. However, we were unable to assemble complete circular genomes for any of the TTVs. The missing segments all overlapped the GC-rich origin of replication that forms stable hairpins and is therefore relatively resistant to sequencing with standard Illumina technology (36). All observed TTV ORF1 sequences belonged to the \textit{Alphatorquevirus} genus and had 51-100% amino acid identity to previously reported TTV strains (Supplemental Table S3).

\textit{Mutation signature analysis}

The overall tumor mutation burden, as measured by non-synonymous mutations per million bases, did not show a clear correlation with the presence of viral sequences (Figure 6A). We analyzed likely somatic point mutations from all tumors and deconvoluted mutation signatures (Figures 6B and 6C, Supplemental Figure S5). As expected for bladder cancer, we commonly observed single-base substitution 2 (SBS2) and SBS13 (both characteristic of APOBEC3
mutagenesis, N=13 cases) and SBS5 (associated with smoking history and ERCC2 mutations, N=11 cases).

Four tumors (TBC16, TBC28, TBC31, TBC33) carried a predominant SBS22 signature, which is caused by the chemical aristolochic acid found in the birthwort family of plants. Cases with this signature showed a very high mutational burden (Figure 6A). In support of the idea that cases with strong SBS22 signatures arose through environmental exposure, one such case, a kidney recipient, was previously diagnosed with Chinese herbal medicine nephropathy. The final deconvoluted signature closely matched the mutation spectrum caused by the deoxy-guanosine analog, ganciclovir, recently identified in hematopoietic stem cell transplant recipients (Figure 6B) (37).

Recurrent somatic mutations

Numerous cellular genes were found to recurrently harbor nonsynonymous, nonsense, and frameshift mutations (Figure 6E). The spectrum of frequently mutated genes is similar to those reported in various types of urothelial carcinoma (e.g., mutations in KMT2D, KDM6A, and ARID1A) (Supplemental Table S5)(20, 38, 39). No nonsynonymous mutations were identified in FGFR3 or PIK3CA, even though these genes are commonly mutated in non-muscle invasive bladder cancer (NMIBC) (40). Mutations in TP53, which are common in muscle-invasive bladder cancer (20), were detected in four tumors (Figure 6E).

To address the reproducibility of mutation calls in deep sequencing of FFPE samples, we analyzed the sequences from two independent sections from separate blocks for three tumors (Figure 6D). Comparing the variants called in these tumors, 77-82% of inferred somatic mutations were common to both sections. Furthermore, a similar comparison showed a large percentage of variants in common between primary tumors and their metastases (Figure 6D). In
TBC06, 84% of the likely somatic mutations in the metastasis were found in the primary tumor, whereas only 28% of the likely somatic variants in the primary tumor were found in the metastasis. In an additional primary-metastatic pair (TBC34), we identified a similar proportion of shared “trunk” mutations but the metastasis had more unique, likely somatic variants.

Discussion

This report presents a comprehensive molecular assessment of 43 bladder cancers arising in solid organ transplant recipients by WGS and total RNA sequencing. DNA and/or RNA sequences of human BK or JC polyomaviruses were detected in 16 tumors (37%). Expression of the polyomavirus LTAg was documented immunohistochemically in ten cases. HPV sequences were detected in six cases, including four cases with HPV types known to cause cervical cancer. Overall, this is a much higher frequency of small DNA tumor virus sequence detection compared to prior surveys of bladder cancers affecting the general population, where fewer than 5% of tumors harbor small DNA tumor virus sequences (3, 41). The results suggest that human polyomaviruses and papillomaviruses can play a carcinogenic role in the development of bladder cancer, particularly among transplant recipients.

BKPyV infection in organotypic urothelial cell culture has been shown to promote cellular proliferation, consistent with the known transforming effects of its T antigens (42). Interestingly, we observed frequent clonal loss of the p53-inactivating helicase domain of BKPyV LTAg due to deletions and point mutations in the integrated virus. While such deletions in LTAg are commonly observed in MCPyV-positive Merkel cell carcinoma (14), MCPyV LTAg lacks the p53-inactivating activity of the C-terminal helicase domain of BKPyV. One might thus have expected the C-terminal portion of BKPyV LTAg to be preserved in tumor cells. We speculate that the loss of the BKPyV helicase domain is driven by negative selection against deleterious effects of LTAg on tumor survival (e.g., LTAg might unwind the integrated BKPyV origin of replication and initiate “onion skin” DNA structures leading to chromosomal instability and cell death). The
absence of the p53-binding domain may be compensated for in some BKPyV-positive tumors through the significantly increased expression of the ubiquitin ligase TRIM71 that we observed. TRIM71 has been shown to bind and poly-ubiquitinate p53 for proteasomal degradation and prevent apoptosis during stem cell differentiation (43).

We also observed amplification of the host genome surrounding BKPyV integration sites, consistent with circular DNA intermediates and/or MMEJ break-induced replication. Similar findings have been reported for HPV and MCPyV-associated tumors (33, 44). These amplification events result in a variable number of tandem head-to-tail copies of the virus and host genome that are thought to create super-enhancers affecting viral and host gene expression (45, 46). In cervical cancer, frequently only one integration event is transcriptionally active; however, in tumors carrying integrated BKPyV sequences, the abundance of viral DNA and RNA are positively correlated, suggesting that each integrated copy produces viral transcripts. While the observed integration sites in this study are unique and have not been observed in Merkel cell carcinoma, HPV16 integration has been reported previously in BCAR3 (47). Elevated expression of BCAR3 has been shown to increase proliferation, motility, and invasiveness of estrogen receptor-positive breast cancer cells after treatment with antiestrogens (48, 49).

In five tumors harboring integrated BKPyV sequences (TBC02, TBC03, TBC05, TBC06 and TBC08), we observed significant upregulation of genes associated with cell cycle progression, DNA damage, histones, and the mitotic spindle. Tumors with evidence of BKPyV integration also exhibited significant downregulation of keratins and cell adhesion genes. The latter may contribute to the high grade and invasive behavior of BKPyV-positive tumors observed in this study and others (50-54).

Many of the observed gene expression changes are consistent with known effects of BKPyV infection and the specific activities of LTAg, which binds Rb-family proteins and alters the active pool of E2F transcription factors in the cell (55, 56). Recent studies have shown that
APOBEC3B expression is repressed by the DREAM complex (which is composed of Rb-family proteins and E2F transcription factors (30)) and, accordingly, we found that APOBEC3B is more highly expressed in BKPyV-positive tumors compared to normal tissues and tumors without tumor virus sequences likely due to LTAg activity. However, despite this increased expression, the mutation signature commonly attributed to APOBEC3B did not appear enriched in BKPyV-positive tumors versus other tumors. It is possible that tumors expressing BKPyV LTAg and increased APOBEC3B manifested greater intratumor heterogeneity, but we were unable to detect possible low frequency APOBEC3-mediated variants from FFPE tissue without deeper and more accurate sequencing. Additionally, consistent with the disruption of the DREAM complex in these tumors, we observed higher expression of MYBL2, a key component of the MMB complex, and one of its targets, FOXM1, which regulates numerous genes required for G2/M progression. We also observed increased expression of FOXM1 downstream targets associated with the centromere and kinetochore, which have been shown to promote improper chromosome segregation and tumorigenesis (57-59).

BKPyV-positive tumors in our study had significantly higher expression of a number of genes that promote homologous recombination (e.g. RAD51, RAD54L, BRCA1, and BRCA2) and protect against replication fork stalling and collapse (e.g RAD51, XRCC2, and FANCB) relative to virus-negative tumors (60). Claspin (CLSPN) and TIMELESS, which interact with replicative polymerases and helicases are also highly expressed in BKPyV-positive tumors, further promoting replication fork progression and genome stability (61). This expression pattern might promote cell survival in the face of genomic damage caused by viral genome integration, oncogene expression, and APOBEC3B upregulation.

While HPVs are not generally considered causative agents of bladder cancer, they have been detected in rare cases of bladder cancer affecting immunocompetent and immunosuppressed patients (2, 3, 62). In the current study, we identified four tumors with carcinogetic Alphapapillomavirus sequences (HPV16 or HPV51). Alphapapillomaviruses are
believed to cause cancer through sustained expression of their E6 and E7 oncoproteins, which is frequently associated with integration of the papillomavirus genome into the tumor genome.

One case in the panel carried sequences of HPV20, a Betapapillomavirus that can cause cutaneous squamous cell carcinoma in animal model systems (63). The possible involvement of Betapapillomaviruses in skin cancer in the general population remains controversial (64). In epidermodysplasia verruciformis, a rare syndrome caused by defects in zinc-binding proteins EVER1 and EVER2, patients frequently develop non-melanoma skin cancers containing Betapapillomaviruses (65). Expression of E6 and E7 from Betapapillomaviruses has been shown to promote cell survival in the face of ultraviolet radiation damage and other carcinogenic insults (63, 64, 66). In the context of bladder cancer, it is possible that cutaneous papillomaviruses likewise enable the accumulation of carcinogenic DNA damage. Additionally, identification of HPV28, an Alphapapillomavirus that is not generally associated with cervical cancer, suggests more abundant papillomavirus infections of the bladder than previously assumed, with unknown implications for carcinogenesis.

An explanation for the observation that viruses are more prevalent in bladder cancers affecting solid organ transplant recipients compared to cases in the general population is that, in combination with immune suppression, transplant recipients may often become newly infected through transmission from the donor graft at the time of transplantation, perhaps with a different viral genotype than present in the host previously. This phenomenon is commonly observed in kidney transplantation and is associated with BKVN (67), but has not been documented for heart, lung, or liver transplant recipients, who are also included in the current study. The lack of detection of BKPyV genotype IV in this study may indicate that this genotype represents a less carcinogenic strain, reminiscent of “low risk” HPV types that are rarely found in tumors. Additionally, this study and one prior study (68) identified JCPyV in bladder tumors. Based on the high degree of similarity between JCPyV and BKPyV, it seems reasonable to expect that the two species would behave similarly. However, the low abundance of JCPyV RNA and DNA in
these specimens and absence of integration, together with the ubiquity of latent JCPyV infections in the urinary tract, raises the possibility that these observations reflect incidental detection events.

The data from this study and others suggest that in the context of strong immune suppression BKPyV can cause bladder cancer through clonal integration but is rarely detected in tumors of the general population. While most adults are seropositive for BKPyV with at least 10% having detectable BKPyV in the urine, BKPyV is only observed in upwards of 4% of NMIBC cases and less than 0.25% in muscle-invasive bladder cancers in the general population (3, 41). This implies that, while BKPyV LTAg can provide a growth advantage to cells in culture, the large multi-domain antigen may be relatively immunogenic compared to the much smaller oncoproteins encoded by high-risk HPVs or the highly truncated MCPyV LTAg isoforms typically observed in tumors. Immunologic recognition of these tumors may also be impacted by the increased expression of APOBEC3B, which can generate immunogenic neoantigens (69, 70).

Several reports of regression of patients’ BKPyV-positive tumors after reduction of immune suppression support the idea that tumors constitutively expressing BKPyV gene products are readily targeted and controlled by the immune system (71-73). The theoretical immunological costs of viral gene expression for a nascent tumor cell raise the possibility of “hit-and-run” carcinogenesis. The hit-and-run hypothesis invokes the idea that a virus may play a causal role in early stages of carcinogenesis but then become undetectable at more advanced stages of tumor development. Infection of a premalignant cell may promote its growth and survival through the expression of the viral oncogenes. Additionally, expression of viral oncogenes may also promote genome instability through the expression of the mutagenic APOBEC3 enzymes or other mechanisms that further push the cell towards transformation as has been suggested by a recent study of BKPyV infection in differentiated urothelium (74).

The heterogeneous expression of LTAg observed in this study could represent transcriptional silencing or loss of BKPyV DNA from one part of the tumor, supporting the idea
that tumors can lose the need for LTAg expression. Alternatively, our observations could be accounted for by a multistage integration and carcinogenesis process proposed by other recent studies on BKPyV-positive urinary tumors from kidney transplant recipients (75, 76). However, our sequencing experiments support a dominant clonally integrated form likely established early during tumor development in most BKPyV-positive tumors in this study. The only exception to this observation is TBC01, which appears to exhibit a viable BKPyV episome with a rearranged regulatory region present in a small subset of tumor cells. This also suggests that archetypal BKPyV, rather than the more pathogenic rearranged strains found in cases of nephropathy, is more likely to integrate and be preserved into nascent tumor cells. In support of the idea that integration may be a common aspect of BKPyV infection, we identified a clonal BKPyV integrant in the normal bladder specimen from case TBC09 in both the RNA and WGS sequencing that was distinct from the BKPyV integrant observed in the tumor sample. The normal tissue integrant had multiple copies of small T antigen and a large deletion in the regulatory regions (Supplemental Figure S1). Only a few reads from RNA sequencing mapped to the small T antigen region, and histology of the section indicates no tumor cells or LTAg staining, suggesting that the virus did not integrate in the right genomic location or maintain the needed components to drive carcinogenesis.

It remains to be seen whether TTVs contribute to disease in the context of immune suppression. A general model is that these ubiquitous viruses establish a chronic infection that the immune system generally keeps in check, but immune suppression results in increases not only in the abundance but also the diversity of TTVs observed in hosts (77). Indeed, detection of TTVs can serve as an indicator of the degree of overall immune suppression in transplant recipients (78). Interestingly, these viruses, like papillomaviruses and polyomaviruses, also appear to be depleted for APOBEC3 target motifs, consistent with the effects of an evolutionary virus-host arms race (23, 32, 79).
Until recently, this type of molecular assessment from FFPE tissues would have been nearly impossible or badly muddled by the highly damaging effects of formalin fixation and oxidation of nucleic acids over time. Recent advancements in the isolation of nucleic acids, such as low temperature and organic solvent-free deparaffinization, combined with efficient library preparation from low-concentration highly degraded sources, yielded sufficiently high-quality material for WGS variant calling and total RNA sequencing (80). To address the difficulty of accurately calling somatic variants (which can be problematic even from flash frozen or fresh tissues), we called variants using the consensus of three modern variant callers. The lack of matched normal tissues for most cases is a limitation of this work, but our analytical approach accounted for this by focusing the analysis on mutations with >10% allele frequency and those with potential functional effects, and by excluding known germline variants. Our methods were validated internally through the sequencing of separate regions from the same tumor and of primary-metastatic pairs, which reveal similar concordance of mutations as has been reported from flash frozen tissues (81). Our variant calling approach was also validated by the observation that we detected four deconvoluted mutation signatures that match those expected from prior surveys of bladder cancer. However, the low overall coverage of our WGS remains a limitation of this study.

We identified four bladder cancers in kidney transplant recipients that exhibited abundant mutations attributable to aristolochic acid-mediated DNA adducts. Aristolochic acid is a highly nephrotoxic and mutagenic compound produced by birthwort plants, which sometimes contaminate certain types of herbal medicines and grains (82). Exposure to this compound likely contributed to the patients’ need for kidney transplantation, as well as their eventual development of bladder cancer. Highlighting the highly mutagenic nature of this compound, the four cases with dominant aristolochic acid signature were in the top seven for total mutation burden (Figure 6). None of the three tumors had detectable oncogenic viral sequences, but one had detectable TTV. We also identified likely ganciclovir-mediated mutations (37) in most
patients indicating that this common treatment to prevent reactivation of cytomegalovirus in solid organ transplant recipients may promote mutagenesis in the urinary bladder. Unfortunately, ganciclovir treatment history was unavailable for these cases to confirm that this is the origin of this mutation signature in these cases. Ever-decreasing sequencing costs will facilitate additional studies of this type and shed light on rare and understudied tumor types, as well as analyses of lower-grade and pre-cancerous lesions.

Materials and Methods

Sample acquisition and ethics

The Transplant Cancer Match (TCM) Study is a linkage of the US national solid organ transplant registry with multiple central cancer registries (https://transplantmatch.cancer.gov/). We used data from this linkage to identify cases of in situ or invasive bladder cancer diagnosed among transplant recipients. Staff at five participating cancer registries (California, Connecticut, Hawaii, Iowa, Kentucky) worked with hospitals in their catchment areas to retrieve archived pathology materials for selected cases.

We obtained twenty 10-micron sections from formal-fixed paraffin-embedded (FFPE) blocks for cases with available material. At each originating institution, the microtome blade was cleaned with nuclease-free water and ethanol between samples. Single 5-micron sections leading and trailing the twenty sections used for nucleic acid isolation were saved for histochemistry.

The TCM Study is considered non-human subjects research at the National Institutes of Health because researchers do not receive identifying information on patients, and the present project utilizes materials collected previously for clinical purposes. The TCM Study was reviewed, as required, by human subjects committees at participating cancer registries.
Nucleic acid isolation

Samples were simultaneously deparaffinized and digested using 400 µL molecular-grade mineral oil (Millipore-Sigma) and 255 µL Buffer ATL (Qiagen) supplemented with 45 µL of proteinase K (Qiagen). Samples were incubated overnight at 65°C in a shaking heat block. Samples were spun at 16,000 x g in a tabletop microcentrifuge for one minute to separate the organic and aqueous phases. Depending on the presence of visible remaining tissue, some samples were subjected to one or two additional two-hour long digests by the addition of 25 µL of fresh proteinase K buffer. Lysates were stored at 4°C until RNA or DNA isolation.

Lysates were spun at 16,000 x g in a tabletop microcentrifuge for one minute. For DNA isolation, 150 µL of supernatant was moved to a new 1.5 mL tube. 490 µL of binding buffer PM (Qiagen) and 10 µL of 3M sodium acetate were added to the lysate. The mixture was then added to a Qiaquick spin column and spun at 16,000 x g for 30 seconds. Flow-through was reapplied to the spin column for complete binding. The column was washed first with 750 µL of Buffer PE (Qiagen) and then 750 µL of 80% ethanol, spinning at 16,000 x g for 30 seconds and discarding flow-through each time. The column was dried by spinning it at 16,000 x g for 5 minutes. Collection tubes were discarded, and the column was moved to a new microcentrifuge tube. 50 µL of pre-warmed, 65°C 10% buffer EB was applied to the column and incubated for 1 minute. The tube was then spun at 16,000 x g for 2 minutes. DNA quantity and quality were assessed by Qubit (Thermo Fisher) and spectrophotometry (DeNovix). DNA was stored at -20°C until used for library preparation. Only samples with greater than 50ng of DNA were processed for library prep.

For RNA isolation, 150 µL of the remaining clarified lysate was moved to a new tube. 250 µL of buffer PKD (Qiagen) was added and vortexed to mix. The remainder of the RNA extraction process was carried out using a RNeasy FFPE Kit (Qiagen) according to the manufacturer's
protocol. RNA quantity and quality were assessed by spectrophotometry (DeNovix) and TapeStation (Agilent).

**Immunohistochemistry**

FFPE 5-µm thick tissue sections mounted on charged glass slides were stained with antibody against Large T Antigen, clone PAb416 (Sigma Millipore, cat. DP02) which detects LTAg from multiple polyomaviruses. Slides were baked in a laboratory oven at 60°C for 1 hour prior to immunostaining on Ventana Discovery Ultra automated IHC stainer upon following conditions: CC2 (pH9) antigen retrieval for 64 min at 96°C, antibody at concentration 0.5 µg/ml in Agilent antibody diluent (cat. S3022) for 32 min at 36°C, Anti-Mouse HQ-Anti HQ HRP detection system for 12 min with DAB for 4 minutes and Hematoxylin II counterstain for 8 minutes. After washing per manufacturer’s instructions, slides were incubated in tap water for 10 min, dehydrated in ethanol, cleared in xylene, coverslipped with Micromount media (Leica Biosystems) and scanned on AT2 slide scanner (Leica Biosystems) for pathology review. FFPE sections of cell pellets transfected with LTAg and commercial slides of SV40 infected tissue (Sigma, cat. 351S) were used as positive controls.

**Library preparation and sequencing**

50-250 ng of isolated DNA was fragmented in microtube-50 using a Covaris sonicator with the following settings: peak power: 100, duty factor: 30, cycles/burst: 1000, time: 108 seconds. End-repair and A-tailing were performed on fragmented DNA using the KAPA HyperPrep Kit (Roche). NEB/Illumina adaptors were ligated onto fragments with KAPA T4 DNA Ligase for 2 hours at 20°C then treated with 4 µL USER enzyme (NEB) for 15 minutes at 37°C to digest uracil-containing fragments. Ligation reactions were cleaned up using 0.8x AMPure XP beads using the KAPA protocol. NEB dual-index oligos were added to the adaptor-ligated fragments and amplified for 6-8 cycles (depending on the amount of input fragmented DNA) using KAPA.
HiFi HotStart ReadyMix (Roche). Final amplified libraries were cleaned using 1x AMPure beads with the recommended KAPA protocol. Ribosomal sequence-depleted cDNA libraries were prepared using 50 ng of total RNA with the SMARTer Stranded Total RNA-Seq Kit v2 – Pico Input Mammalian (Takara) following the manufacturer instructions for FFPE tissues. Final RNA and DNA libraries were assessed for size and quantity by Agilent TapeStation. Only samples that yielded libraries greater than 5 nM were sequenced.

DNA libraries were sequenced on the Illumina NovaSeq 6000 at the Center for Cancer Research (CCR) Sequencing Facility. RNA libraries were sequenced on the Illumina NovaSeq 6000 and NextSeq 550 in high output mode at the CCR Genomics Core. Sequencing metrics are reported in Supplemental Table S1.

Sequence alignments

Reads were trimmed using Trim Galore 0.6.0 with default settings. RNA reads were initially aligned using STAR aligner 2.5.3ab (83) against a fusion reference human genome containing hg38, all human viruses represented in RefSeq as of December 2018 (Supplemental Table S2), and all papillomavirus genomes from PaVE https://pave.niaid.nih.gov (84). Default parameters were used with the following exceptions: chimSegmentMin=50, outFilterMultimapNmax=1200, outFilterMismatchNmax=30, outFilterMismatchNoverLmax=1. Any reads that had less than 30 bp of perfect identity were excluded. Trimmed DNA reads were aligned with Bowtie2 (2.3.4.3) using the --very-sensitive setting to the same reference genome as mentioned above excluding RNA viruses (85). Alignments were sorted and duplicate sequences were flagged using Picard 2.20.5. Indel realignments and base quality recalculations were conducted using GATK.

Virus detection and integration analysis
All WGS reads not mapping to the human genome were de novo assembled using MEGAHIT
(1.1.4) with default parameters (86). All trimmed RNA reads were assembled using
RNASPAdes (87). Assembled contigs were annotated using BLASTn and BLASTx against the
NCBI nt database (October 2021) for closely related species, and CenoteTaker2
(https://github.com/mtisza1/Cenote-Taker2) was used to identify more divergent species in
contigs \( \geq 1000\text{bp} \) (88). Depth and breadth of coverage of viral species were normalized by total
number of human reads and length of the viral genome. Only species with \( \geq 10\% \) genome
coverage and a normalized depth \( \geq 10 \) for a viral genome in a given sample were considered as
hits. Viral read k-mers were cross-compared against samples for uniqueness to identify index
hopping or potential contamination between samples. Rearrangements in the BKPyV regulatory
region were analyzed and annotated using BKTyper (89).

Bam alignments were input into Oncovirus Tools (github.com/gstarrett/oncovirus_tools) to call
integration sites (33, 90). It starts by extracting discordant read pairs (where one read aligns to a
sequence of interest, i.e. virus, and the mated read aligns to the human genome) and any
remaining reads aligned to the human genome that contain at least one 25bp k-mer from the
input sequences of interest as determined by a Bloom filter. It uses the human genomic
coordinates from the above reads to identify putative integration regions by merging their
stranded mapping positions to find overlaps, counting the number of reads per stranded region.
Oncovirus Tools then assembles the extracted reads, together with all unaligned reads, using
Spades (91). The resulting assembly graphs are annotated with the human and viral genomes
using BLASTn and the annotated assembly graphs are plotted using the R package ggraph.
The output is then screened for contigs containing both human and viral hits with BLASTn e-
values below \( 1e^{-10} \). Based on these hits, integration junctions are called and overlaps in host-
virus hits on the contigs are then screened for microhomology. All putative integration sites from
Oncovirus Tools were manually validated by returning to the original alignment file.
Transcriptome clustering and differential gene expression analysis

Counts from STAR were input into R and normalized using the DESeq2 vst function (92). The DESeq2 model was built using the following factor: tissue type (normal, primary, metastasis), grade, stage, and virus status to evaluate their effects on gene expression. Since the RNA seq libraries were prepared in different batches on different days and in different sequencing runs, batch effects were removed using the R package limma and the function RemoveBatchEffects. These normalized counts were input into the R package ConsensusClusterPlus. Pathway analysis was conducted using Enrichr (https://amp.pharm.mssm.edu/Enrichr) (93, 94).

Somatic point mutation, structural variant, and copy number variant calling

Point mutations were called using Mutect2, VarScan2 and lofreq with default parameters (95, 96). Consensus calls between these variant callers were performed using SomaticSeq (3.3.0) (97). Likely germline variants were annotated and removed using SnpSift and dbSNP v152. Likely somatic point mutations were further filtered by the following criteria: SomatiqSeq PASS filter, ≥10% allele frequency, ≥4 reads supporting the variant allele, and ≥8 reads of total coverage of that position. Common mutations in cancer were annotated using SnpSift and COSMIC. Copy number variants in tumor WGS datasets were called using GATK4 CNV to compare them to a panel comprised of the normal-tissue WGS datasets generated in this study. Recurrent copy number variants within polyomavirus-containing tumors or tumors with no virus were determined using GISTIC2 with default parameters. Visualization and variant calling for BKPyV was performed on alignments against a BKPyV genotype Ib-2 isolate (accession number: AB369087.1).

Mutation signature analysis
Mutation signature analysis was conducted using the likely somatic variants passing all the
above criteria. Mutational Patterns and Somatic Signatures R packages were used for de novo
somatic mutations signature analysis.

Data visualization
All graphs were made in the R statistical environment (4.0.3) using the package ggplot2 or using
Graphpad Prism.

Availability of data and materials
All refseqs for human papillomaviruses were downloaded from PaVE and refseqs for human
polyomaviruses were downloaded from NCBI as of November 2018. All data generated in this
study will be available from dbGaP under accession #######. Viral contigs from this study will be
deposited in GenBank under accessions #######. Code used in this manuscript are available
from www.github.com/gstarrett.

Funding
This work was funded by the NIH Intramural Research Program.

Acknowledgments
We would like to thank the CCR Genomics Core and CCR Sequencing Facility for their
assistance with sequencing. This work utilized the computational resources of the NIH HPC
Biowulf cluster (http://hpc.nih.gov). We would also like to thank the members of the Laboratory
of Cellular Oncology for their useful discussion and insights.
We would like to the staff at the Scientific Registry of Transplant Recipients and participating
cancer registries who assisted with collection of the data and registry linkages.
Disclaimer: The views expressed in this article are those of the authors and should not be interpreted to reflect the views or policies of the National Cancer Institute, the Health Resources and Services Administration, the Scientific Registry of Transplant Recipients, the cancer registries, or their contractors.

References


detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a
polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients
17. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ
Onset of Urinary Tract Cancers in Patients with BK Polyomavirus Associated Nephropathy.
Viruses. 2021;13(3).
cytidine deaminase mutagenesis pattern is widespread in human cancers. Nature genetics.
2013;45(9):970-6.
23. Pouline F, Lejeune N, Willemart K, Gillet NA. Footprint of the host restriction factors
16 E6 up-regulates APOBEC3B via the TEAD transcription factor. Journal of Virology.
2017;JVI.02413-16.
26. Warren CJ, Westrich JA, Doorislaer KV, Pyeon D. Roles of APOBEC3A and APOBEC3B in
Human Papillomavirus Infection and Disease Progression. Viruses. 2017;9(8).
decrease human papillomavirus 16 pseudovirion infectivity. Biochemical and biophysical
papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase
Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-
Independent Mechanism. MBio. 2019;10(1).
of BK Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving


Figure Legends

Figure 1. Detection of viral sequences. A. Primary tumors. B. Metastatic tumors. C. Normal tissues. Viral species are shown on the rows, and each case in the cohort (represented with a TBC number) is a column. Circle size represents the breadth or fraction of the viral genome covered, and color represents the average depth of coverage of the viral k-mers with all coverages over 100 binned together. Specimens without sequencing data have a gray background.

Figure 2. Virus diversity and integration. A. Phylogenetic tree of BKPyV LTAg sequences detected in tumors (red) and reference genotypes. B. Sites of BKPyV integration into host chromosomes are indicated with case numbers. Two separate sections from separate FFPE blocks of the primary tumor were sequenced for case TBC03 (samples TBC03.1 and TBC03.2). Two separate sections were also sequenced for case TBC09, but an integration site was only detected in sample TBC09.1. Integration sites were also detected in normal tissue sample TBC09N. Black and gray bars indicate cytogenetic bands; red bars indicate centromeres. C. Coverage plot of focal amplifications adjacent to BKPyV integration sites in cases TBC03, TBC04, and TBC08. BKPyV integration junctions are indicated by a black arrow. Colored numbers in the body of the graph indicate coverage depth.

Figure 3. BKPyV DNA, RNA and LTAg detection in tumors. A. Barplots showing the abundance of BKPyV DNA and RNA reads standardized to human reads B. Barplots of...
histologically estimated percent tumor purity and IHC-positivity for polyomavirus LTAg expression. C. Representative coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyV-positive tumors. Relative copy numbers are indicated by colored boxes and highlight the borders of duplications and deletions in the viral genome. D. Selected images for LTAg IHC highlighting positive staining for BKPyV-positive tumors with scale bars representing 500 microns.

**Figure 4. Differential gene expression in BKPyV-positive tumors.** A. Volcano plot of differential gene expression between BKPyV-positive and virus-negative tumors. Significantly differentially expressed genes (q-value < 0.05) with a fold change greater than 2 are in red, genes with a fold change less than 2 are in pink. Non-significant genes are in gray. B. Variance stabilized counts for APOBEC3B from DESeq grouped by normal tissues, virus-negative tumors, and BKPyV-positive tumors showing significantly increased expression in BKPyV-positive tumors. C. Heatmap of Z-scores of significantly differentially expressed genes and genes relevant to bladder cancer grouped by gene ontology. High expression is red, low expression is blue. Tumors are colored by likely etiology: BKPyV-positive, red; JCPyV-positive, goldenrod; HR-HPV-positive, blue; TTV-positive, green; aristolochic acid, purple; other, black. Tumors with evidence of integration are in italics.

**Figure 5. Copy number variants.** Frequency plots for large copy number variants in A. BKPyV-positive and C. virus-negative tumors. Frequency of gains/amplifications are shown in red; losses/deletions are shown in blue. Sample level copy number variant spectra for B. BKPyV-positive and D. virus-negative tumors. Complete deletions are in dark blue and high copy amplifications are in red.
**Figure 6. Somatic point mutations and mutation signature analysis.** A. Tumor mutation burden (TMB, non-synonymous mutations per million bases) for each tumor in this study. Bars are colored by viral positivity (red, BKPyV; green, TTV; blue, HR-HPV; goldenrod, JCPyV) or etiologic agent (aristolochic acid, purple). B. Barplots of the contribution each trinucleotide substitution for the four deconvoluted signatures with the likely mutation process indicated. C. Proportion of each deconvoluted signature that contributes to each sample with virus status indicated by colored circles (red, BKPyV; green, TTV; blue, HR-HPV; goldenrod, JCPyV). D. Number of unique and common trunk mutations in primary-metastatic tumor pairs and tumors with multi-region sequencing. For TBC03, TBC09, and TBC28, branches 1 and 2 refer to two separate areas of the same tumor. For TBC06 and TBC34, branches P and M refer to the primary tumor and metastasis, respectively. E. Oncoprint for the top mutated genes in bladder cancers of transplant patients. Tumors IDs are colored by likely etiology: BKPyV-positive, red; JCPyV-positive, goldenrod; HR-HPV-positive, blue; TTV-positive, green; aristolochic acid, purple; other, black.
### Table 1. Characteristics of post-transplant bladder cancer cases (N=43)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Statistic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, N (%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>13 (30)</td>
</tr>
<tr>
<td>Male</td>
<td>30 (70)</td>
</tr>
<tr>
<td>Age in years at diagnosis, median (IQR)</td>
<td>65 (60, 71)</td>
</tr>
<tr>
<td>Transplanted organ, N (%)</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>24 (56)</td>
</tr>
<tr>
<td>Liver</td>
<td>4 (9)</td>
</tr>
<tr>
<td>Heart and/or lung</td>
<td>14 (33)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Race, N (%)</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>30 (70)</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>7 (16)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>5 (12)</td>
</tr>
<tr>
<td>Years from transplant to diagnosis, median (IQR)</td>
<td>5.8 (3, 7)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>6.0 (4,8)</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>4.7 (3,8)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1.1 (1,8)</td>
</tr>
<tr>
<td>Summary stage, N (%)</td>
<td></td>
</tr>
<tr>
<td>In situ</td>
<td>12 (28)</td>
</tr>
<tr>
<td>Localized</td>
<td>19 (46)</td>
</tr>
<tr>
<td>Regional</td>
<td>7 (14)</td>
</tr>
<tr>
<td>Distant</td>
<td>5 (12)</td>
</tr>
<tr>
<td>Grade, N (%)</td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>20 (47)</td>
</tr>
<tr>
<td>High</td>
<td>22 (51)</td>
</tr>
<tr>
<td>Papillary urothelial neoplasm of low malignant potential</td>
<td>1 (2)</td>
</tr>
</tbody>
</table>
## Table 2. BKPyV integrations sites and microhomology

<table>
<thead>
<tr>
<th>ID</th>
<th>Human sequence match</th>
<th>Virus sequence match</th>
<th>Maximum MH length</th>
<th>MH/Sequence</th>
<th>Chromosome</th>
<th>Position</th>
<th>Nearest Gene (Symbol)</th>
<th>Nearest Gene (Ensembl ID)</th>
<th>Nearest RE</th>
<th>Distance to Nearest Gene</th>
<th>Nearest RE</th>
<th>Distance to Nearest RE</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBC01</td>
<td>CATGATTAGACGTAGGG</td>
<td>CATGATTAGACGTAGGG</td>
<td>5</td>
<td>CATGATTAGACGTAGGG</td>
<td>chr2</td>
<td>12037801</td>
<td>INHBB</td>
<td>ENSG00000163083</td>
<td>569b</td>
<td>377</td>
<td>0</td>
<td>377</td>
</tr>
<tr>
<td>TBC02</td>
<td>CTGGACATTGAACTCC</td>
<td>CTGGACATTGAACTCC</td>
<td>5</td>
<td>CTGGACATTGAACTCC</td>
<td>chr4</td>
<td>55783385</td>
<td>C4orf51</td>
<td>ENSG00000237136</td>
<td>353</td>
<td>353</td>
<td>0</td>
<td>353</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>GCTGTTGATTCCATAGTA</td>
<td>GCTGTTGATTCCATAGTA</td>
<td>2</td>
<td>GCTGTTGATTCCATAGTA</td>
<td>chr1</td>
<td>81395546</td>
<td>BC031447</td>
<td>BC031447</td>
<td>0</td>
<td>0</td>
<td>377</td>
<td>377</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>SGCAGGCGGCGGTTGAG</td>
<td>SGCAGGCGGCGGTTGAG</td>
<td>4</td>
<td>SGCAGGCGGCGGTTGAG</td>
<td>chr12</td>
<td>95764260</td>
<td>LARP4</td>
<td>ENSG00000161813</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>2</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>chr3</td>
<td>76020484</td>
<td>PPP4R2</td>
<td>ENSG00000163605</td>
<td>0</td>
<td>0</td>
<td>69</td>
<td>69</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>TTTTCTTCTTTTCTTCTT</td>
<td>TTTTCTTCTTTTCTTCTT</td>
<td>7</td>
<td>TTTTCTTCTTTTCTTCTT</td>
<td>chr3</td>
<td>76020484</td>
<td>PPP4R2</td>
<td>ENSG00000163605</td>
<td>0</td>
<td>0</td>
<td>69</td>
<td>69</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>GCTGTTGATTCCATAGTA</td>
<td>GCTGTTGATTCCATAGTA</td>
<td>2</td>
<td>GCTGTTGATTCCATAGTA</td>
<td>chr16</td>
<td>12375232</td>
<td>EN3G00000135542</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>TBC03.1</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>2</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>chr18</td>
<td>90375500</td>
<td>PLCB1</td>
<td>ENSG00000182621</td>
<td>0</td>
<td>0</td>
<td>995</td>
<td>995</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>2</td>
<td>CAATTGGGTGGGTTGAG</td>
<td>chr20</td>
<td>11256282</td>
<td>PLGB1</td>
<td>ENSG00000182621</td>
<td>0</td>
<td>0</td>
<td>995</td>
<td>995</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>TAAAGTGACATGGGTAG</td>
<td>TAAAGTGACATGGGTAG</td>
<td>8</td>
<td>TAAAGTGACATGGGTAG</td>
<td>chr20</td>
<td>11256282</td>
<td>PLGB1</td>
<td>ENSG00000182621</td>
<td>0</td>
<td>0</td>
<td>995</td>
<td>995</td>
</tr>
<tr>
<td>TBC03.1</td>
<td>TAAAGTGACATGGGTAG</td>
<td>TAAAGTGACATGGGTAG</td>
<td>8</td>
<td>TAAAGTGACATGGGTAG</td>
<td>chr20</td>
<td>11256282</td>
<td>PLGB1</td>
<td>ENSG00000182621</td>
<td>0</td>
<td>0</td>
<td>995</td>
<td>995</td>
</tr>
</tbody>
</table>

### Supporting Information Legends

**Figure S1.** All SV40 LTAg staining, BKPyV DNA/RNA coverage, and regulatory region structures. A. Coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyV-positive tumors. B. Selected images for LTAg IHC highlighting positive staining for BKPyV-positive tumors with a scale bar representing 500 microns. C. Heatmap of normalized expression (transcripts per 38
million, TPM) of BKPyV genes per tumor. D. Diagrams of BKPyV NCCR structures and rearrangements in tumors. P=Primary tumor, M=metastatic tumor.

**Figure S2. APOBEC3B germline variant and expression by BKPyV status.** Stabilized counts of APOBEC3B expression divided by tissue type (primary tumor, normal tissue), BKPyV status (BK), and germline variant rs1014971 status.

**Figure S3. All JCPyV DNA/RNA coverage plots.** Representative coverage plots for JCPyV DNA (gray) and RNA (red) in JCPyV-positive tumors.

**Figure S4. All HPV DNA/RNA coverage plots.** Representative coverage plots for HPV DNA (gray) and RNA (red) in HPV-positive tumors. Diagrams of open reading frames for each respective type are below the coverage plots.

**Figure S5. Mutations signature deconvolution.** A. Residual sum of squares and explained variance for 2-10 signatures deconvoluted by SomaticSignatures. B. Barplot of base substitution contributions to each of the four deconvoluted signatures from SomaticSignatures. C. Heatmap of cosine similarities of four signatures deconvoluted by Somatic Signatures versus known Single Base Substitution Signatures (SBS). D. NMF rank survey results for 2-10 signature deconvolution by MutationalPatterns. E. Barplot of base substitution contributions to each of the four deconvoluted signatures from MutationalPatterns. F. Heatmap of cosine similarities of four signatures deconvoluted by MutationalPatterns versus known Single Base Substitution Signatures (SBS) with closest matches highlighted in red.

Table S1: Sequencing metrics

Table S2: Reference sequences used in this study
1 Table S3. Tumor torque teno virus similarities
2 Table S4: BKPyV-positive tumor vs virus-free tumor significantly differentially expressed genes
3 Table S5. Non-synonymous point mutations
4 Table S6. Copy number variants
Figure 2

A

B

C

TBC03 (chr1) 17 kb BKPyV integration site

TBC04 (chr3) 15 kb

TBC08 (chr6) 195 kb

Figure 2 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2022. doi: medRxiv preprint
Normal tissues: Virus-negative tumors

BKPyV+ tumors

Stabilized count

AMOT
HMGB2
LEP
SHH
SMO
TP53
TP63
CD44
CD47
CDH1
DSC3
FAT2
FLNC
LAMB3
LY6D
MIFAP4
MUC2
MUC4
VIM
AURKB
CCND1
CDKN2A
CDKN2C
CDKN3
MELK
MYBL2
TRIM71
BMP5
ERBB2
FGFR3
FOXA1
GATA3
ID3
PDXK
PPARG
SCIN
TBX3
WNT5A
ZEB1
ZEB2
APOBEC3B
CLSPN
FANCB
RAD51
RAD54L
KRAS
H1-5
H2BC11
H3C12
CD27
CD27T
CXCL3
IL17A
IL17F
PDCD1
PDCD1LG2
IGHV1-2
IGHV3-13
IGHV4-31
IGLV1-5
KRT13
KRT14
KRT15
KRT16
KRT20
KRT25
KRT6C
KRT7
KRT8
KRT9
KRT20
KRT28
LAMC2
LAMB3
LY6D
MIFAP4
MUC2
MUC4
VIM
AURKB
CCND1
CDKN2A
CDKN2C
CDKN3
MELK
MYBL2
TRIM71
BMP5
ERBB2
FGFR3
FOXA1
GATA3
ID3
PDXK
PPARG
SCIN
TBX3
WNT5A
ZEB1
ZEB2
APOBEC3B
CLSPN
FANCB
RAD51
RAD54L
KRAS
H1-5
H2BC11
H3C12
CD27
CD27T
CXCL3
IL17A
IL17F
PDCD1
PDCD1LG2
IGHV1-2
IGHV3-13
IGHV4-31
IGLV1-5
KRT13
KRT14
KRT15
KRT16
KRT20
KRT25
KRT6C
KRT7
KRT8
KRT9
KRT20
KRT28

Figure 4

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is available for use under a CC0 license.
Figure 5

Proportion of Gains/losses for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprintthis version posted August 13, 2022. ; https://doi.org/10.1101/2021.11.11.21266080doi: medRxiv preprint